论文部分内容阅读
目的:观察中医辨证论治联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法:将92例NSCLC住院患者按随机抽签法分为观察组和常规组各46例,均实施化疗,观察组患者同时给予中医汤剂,观察比较两组患者的临床疗效。结果:观察组患者控制率为78.2%,明显高于常规组的52.1%,且观察组患者不良反应发生情况较常规组轻(P<0.05),差异具有统计学意义(P<0.05)。两组的远期生存情况差异无统计学意义(P>0.05)。结论:中医辨证论治联合化疗治疗晚期NSCLC患者可增效减毒,提高疾病控制率,有延长无病生存率及总生存期的趋势。
Objective: To observe the clinical effect of TCM syndrome differentiation combined with chemotherapy on advanced non-small cell lung cancer (NSCLC). Methods: Ninety-two patients with NSCLC were randomly divided into observation group and conventional group, 46 patients in each group were treated with chemotherapy. The patients in observation group were also given decoction of Chinese medicine. The clinical curative effect was observed and compared between the two groups. Results: The control rate in the observation group was 78.2%, which was significantly higher than that in the conventional group (52.1%). The incidence of adverse reactions in the observation group was lighter than that in the conventional group (P <0.05). The difference was statistically significant (P <0.05). There was no significant difference in long-term survival between the two groups (P> 0.05). Conclusion: TCM syndrome differentiation and chemotherapy combined with chemotherapy in patients with advanced NSCLC can increase efficiency and reduce toxicity, improve disease control rate, there is a trend to extend the disease-free survival rate and overall survival.